Unadjusted and adjusted* HRs for morbidity between 1980 and 2013 from all cancer and breast cancer in the groups given folic acid supplements in the Aberdeen folic acid supplementation trial, 1966–1967
| n | Unadjusted HR (95% CI; p value) | p For trend | Adjusted HR* (95% CI; p value) | p For trend | |
|---|---|---|---|---|---|
| All cancer morbidity | |||||
| Placebo | 292 | 1.00 | 0.97 | 1.00 | 0.88 |
| 0.2 mg folic acid | 68 | 0.98 (0.75 to 1.28; 0.88) | 1.06 (0.81 to 1.39; 0.68) | ||
| 5 mg folic acid | 72 | 1.01 (0.78 to 1.31; 0.93) | 1.12 (0.86 to 1.46; 0.40) | ||
| Breast cancer morbidity | |||||
| Placebo | 98 | 1.00 | 0.67 | 1.00 | 0.38 |
| 0.2 mg folic acid | 19 | 0.82 (0.50 to 1.34; 0.42) | 0.86 (0.52 to 1.42; 0.57) | ||
| 5 mg folic acid | 28 | 1.17 (0.77 to 1.78; 0.47) | 1.29 (0.84 to 2.00; 0.25) | ||
*Adjusted for maternal age, smoking, height, weight, social class and gestational age.